Edward Heart Hospital has become the first facility in Illinois, USA, to use the Corindus Vascular Robotics CorPath system. This product is the first US Food and Drug Administration (FDA)-cleared medical device for robotically-assisted percutaneous coronary interventions (PCI), according to a press release.
“From our first case, we have used the CorPath system to successfully perform complex PCI,” says Mark Goodwin, chief of Cardiology, Edward Heart Hospital. “Our whole team is very excited to be leaders in bringing this technology to our patients and this protection to our staff.”
“With the CorPath system, the physicians at Edward Heart Hospital are able to leverage robotic precision and protection for their expanding practice and complex case load,” states David Handler, president and chief executive officer of Corindus. “We are very pleased to be working with [Edward Heart] and to have such a prestigious Chicago hospital using our technology.”
The CorPath system is designed to allow interventional cardiologists to perform procedures away from the patient bed side and the radiation source. Seated in a radiation-protected cockpit, the physician uses digital controls to robotically advance catheters, angioplasty balloons and stents to clear the blockage in the heart and restore blood flow. Additionally, the technology is intended to provide interventional cardiologists with the ability to accurately measure relevant anatomy, which may lead to fewer stent implants.